Our model of t-dEVs from IRF5-high and IRF5-low tumor cell lines provides additional pre-clinical evidence for altering the landscape of a tumor microenvironment and its PMN by packaging IRF5 into EV-like nanoparticles for therapeutic delivery. This evidence concerns the gene IRF5 and neoplasm.